Sign Up Today and Learn More About Paige Stock
Invest in or calculate the value of your shares in Paige or other pre-IPO companies through EquityZen's platform.
About Paige Stock
Founded
2018
Headquarters
New York, NY, US
Industries
Software, Artificial Intelligence, Data and Analytics
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
Paige Press Mentions
Stay in the know about the latest news on Paige
Gestalt and Paige Partner to Enhance Digital Pathology Workflows with Integration of Advanced AI Algorithms
prnewswire • Nov 01, 2024
Medical startup Paige unveils Alba AI all-in-one assistant for pathology research
venturebeat • Sep 06, 2024
Indica Labs and Paige Forge Strategic Partnership to Expand Integrated AI for Anatomic Pathology Labs
pharmiweb • Aug 27, 2024
Paige and Microsoft roll out updated image-based AI models for cancer diagnosis
fiercebiotech • Aug 12, 2024
Paige publishes open-source AI pathology models for cancer R&D
fiercebiotech • Aug 05, 2024
Paige Management
Leadership team at Paige
Founder & Chief Scientific Officer
Thomas Fuchs
CEO
Leo Grady
Join now and verify your accreditation status to gain access to:
- Paige current valuation
- Paige stock price
- Available deals in Paige and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Paige Stock
How to invest in Paige stock?
Accredited investors can buy pre-IPO stock in companies like Paige through EquityZen funds. These investments are made available by existing Paige shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Paige stock?
Shareholders can sell their Paige stock through EquityZen's private company marketplace. EquityZen's network includes over 340K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 44K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
